Search

Your search keyword '"Khoo, Saye"' showing total 1,616 results

Search Constraints

Start Over You searched for: Author "Khoo, Saye" Remove constraint Author: "Khoo, Saye"
1,616 results on '"Khoo, Saye"'

Search Results

3. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

8. Clinical and population‐based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy

9. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

13. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

14. A multi-country analysis of COVID-19 hospitalizations by vaccination status

15. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

16. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

17. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial

18. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

19. A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin

20. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

21. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

22. Clinical features and management of human monkeypox: a retrospective observational study in the UK

26. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

29. Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.

31. Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.

32. Optimisation of SARS-CoV-2 culture from clinical samples for clinical trial applications

33. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells

34. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

35. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

37. Polypharmacy and Drug–Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study

39. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.

40. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.

41. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

43. Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

44. Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six Months

46. Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin

47. Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.

50. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

Catalog

Books, media, physical & digital resources